Comparative Pharmacology
Head-to-head clinical analysis: MAXAIR versus THEOCLEAR 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXAIR versus THEOCLEAR 100.
MAXAIR vs THEOCLEAR-100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular cAMP.
Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular cAMP, and antagonizing adenosine receptors.
2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.
100 mg orally every 6 hours; adjust based on serum theophylline concentrations and clinical response (target 5-15 mcg/mL).
None Documented
None Documented
3.5–4.0 hours; clinically, this supports dosing every 4–6 hours as needed.
Terminal elimination half-life is approximately 8-12 hours in healthy adults. In smokers, half-life is reduced by 50%; in patients with hepatic cirrhosis or heart failure, half-life is prolonged to 24-36 hours.
Renal excretion of unchanged drug accounts for approximately 90% of elimination; fecal excretion is minimal (<5%).
Renal excretion accounts for approximately 10% of the administered dose as unchanged drug. The remainder is hepatically metabolized, with metabolites excreted renally. Biliary/fecal elimination is negligible (<5%).
Category C
Category C
Bronchodilator
Bronchodilator